1. Over a third of infant peanut allergy diagnoses are wrong
Of 778 Australian infants with a peanut reaction in their history and a positive allergy test, 271 ate their way through a supervised peanut challenge without reacting. That's 34.8% of babies carrying an allergy label they didn't earn.
The data comes from ADAPT, the national infant peanut oral immunotherapy program. It's run by Murdoch Children's Research Institute, the National Allergy Centre of Excellence and 10 paediatric public hospitals across Victoria, NSW, Queensland, SA and WA. Since 2024, eligible infants get a threshold oral food challenge before starting OIT. To qualify, they need a CoFAR grade 1 or 2 reaction before 12 months, plus an SPT of at least 3mm or sIgE of at least 0.35kUA/L. The challenge is seven escalating doses, from 15mg to 1300mg, given 15 minutes apart.
The tests helped only at the extremes. Every infant with Ara h 2 sIgE of 5.0kUA/L or more, or an SPT of 12mm or more, reacted. In between, history plus a positive test wasn't enough to call it. Neither test predicted how severe a reaction would be. Of 29 infants with a grade 3 history who had this challenge, 48.3% tolerated peanut.
Challenges carry real risk. Anaphylaxis occurred in 7.8% of all challenges. All were managed safely, which is why the authors want challenges done in centres equipped for severe reactions. For infants who did react, the challenge threshold set their OIT starting dose, and 97.5% started successfully.
Peanut allergy affects about one in 30 Australian kids. That adds up to a lot of families avoiding peanut, and possibly facing years of treatment, without needing to.
The takeaway: When an infant comes in with a reaction and a positive SPT or sIgE, tell parents the diagnosis isn't confirmed yet. Refer to a paediatric allergy service for a supervised challenge rather than locking in lifelong avoidance.